| Bioactivity | PF-06882961 is a potent, orally bioavailable agonist of the glucagon-like peptide-1 receptor (GLP-1R)[1][2]. | ||||||||||||
| Target | GLP-1R | ||||||||||||
| In Vivo | PF-06882961 (3-240 mg per day) shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat[3].PF-06882961 (3-240 mg per day) results one death in an earlier 2-week monkey study at the highest PF-06882961 dose given in that study. No deaths are seen in the 6-week monkey study or any other monkey studies at any of the doses given[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: | ||||||||||||
| CAS | 2230198-02-2 | ||||||||||||
| Formula | C31H30FN5O4 | ||||||||||||
| Molar Mass | 555.60 | ||||||||||||
| Appearance | 固体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. 20th SCI/RSC Medicinal Chemistry Symposium. [2]. Méndez M, et al. Design, Synthesis, and Pharmacological Evaluation of Potent Positive Allosteric Modulators of the Glucagon-like Peptide-1 Receptor (GLP-1R). J Med Chem. 2019 Oct 23. [3]. POSSIBLE SIDE EFFECTS AND RISKS OF THE STUDY DRUG AND PROCEDURES. |